Capsaicin bioactive in cabai (capsicum annum l.) as anticancer through inhibition of over ekspresi protein target rac-alpha serine/threonine-protein kinase (akt1) and mitogen-activated protein kinase 1 (mapk1) on hepatocyt cell mice (mus musculus)

Capsaicin is a secondary metabolite of the Chilean plant. In the pharmaceutical field in addition to relieving pain or pain, capsaicin is also known to have anticancer activity because it inhibits certain oncogenic proteins. Screening of components in Capsicum Annum L. against the target proteins AKT1 and MAPK1 is needed as an initial stage of drug discovery. Further screening of Capsaicin compounds for oncogenic proteins produced in Hepatocellular carcinoma (HCC) pathogenesis signaling. In silico data that have been obtained, Capsaicin in chili (Capsicum Annum L.) has a high affinity for MAPK1 and AKT1 receptor/protein targets with energy and potential activity score (Pa) 0.690 for preneoplastic treatment, 0.590 for apoptotic agonists, and 0.366 for antineoplastic activity. Statistical data using Kruskal Wallis obtained information that Capsaicin can inhibit the expression of AKT 1 and MAPK 1 on mice hepatocyte cells induced by AFB1 in vivo administration, therefore it can be a candidate for anticancer drugs.